Phase I safety & preliminary acceptability of nonoxynol-9 vaginal pessary as a vaginal microbicide in low risk women in Pune, India.
OBJECTIVE
Though nonoxynol-9 (N-9) is available in India as a spermicidal pessary, data on its safety as a potential microbicide among Indian women are not available. Nonoxynol-9 containing compounds have shown anti-HIV activity in in vitro studies and protection against cervical infections. Nonoxynol-9 is being extensively evaluated as a vaginal microbicide world-wide. We assessed the safety and preliminary acceptability of nonoxynol-9 pessary as a vaginal microbicide in women at low risk for human immunodeficiency virus (HIV) infection and sexually transmitted diseases (STDs).


METHODS
Twenty three HIV seronegative women enrolled in the study were given Today pessarys containing 5 per cent of nonoxynol-9 for vaginal use at bedtime for 14 days. Colposcopy was done at enrollment and on day 14 and speculum examination on day 7 to assess the local toxicity.


RESULTS
Most of the women (16/23, 69.6%) did not experience any symptoms of genital irritation. The remaining 7 (30.4%, 95% CI 11.6-49.2) women reported 11 episodes of mild irritative symptoms of short duration. On clinical examination, three adverse events were reported of which one could have been product related. Eight (34.8%) women showed willingness to use the product for protection against HIV transmission if it was approved.


CONCLUSIONS
Nonoxynol-9 vaginal pessary was found to be safe and acceptable in once daily dose in low risk women after consecutive use for 14 days. Willingness for future use, if found safe and effective for HIV prevention was shown by 8 (34.8%) women.
Joshi
S
S
National AIDS Research Institute (ICMR), Bhosari, Pune, India.
Joglekar
N
N
Ghate
M
M
Unni
J
J
Risbud
A
A
Bentley
M
M
Shepherd
M
M
Bollinger
R
R
Mehendale
S
S
D000282:Administration, Intravaginal; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003127:Colposcopy; D005260:Female; D015658:HIV Infections / Q000517:prevention & control; D018023:HIV Seronegativity; D006801:Humans; D007194:India; D017137:Nonoxynol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010570:Pessaries; D012307:Risk Factors
D000890:Anti-Infective Agents; D017137:Nonoxynol